{"doi":"10.1097/jto.0b013e31823c5aee","title":"EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib","abstract":null,"journal":"Journal of Thoracic Oncology","year":2012,"id":684616,"datarank":0.4636563680037475,"base_score":3.091042453358316,"endowment":3.091042453358316,"self_citation_contribution":0.4636563680037475,"citation_network_contribution":0.0,"self_endowment_contribution":0.4636563680037475,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":21,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":33776,"name":"M. Catherine Pietanza","orcid":"0000-0002-5663-661X","position":1,"is_corresponding":false},{"id":1788550,"name":"Dana Aftab","orcid":null,"position":2,"is_corresponding":false},{"id":235766,"name":"Ronglai Shen","orcid":"0000-0002-8192-7531","position":3,"is_corresponding":false},{"id":361424,"name":"Zhiguo Zhao","orcid":"0000-0002-9033-7410","position":4,"is_corresponding":false},{"id":748068,"name":"Xi Chen","orcid":"0000-0002-1570-6925","position":5,"is_corresponding":false},{"id":1788551,"name":"Katherine Hutchinson","orcid":null,"position":6,"is_corresponding":false},{"id":1353997,"name":"Agnes Viale","orcid":null,"position":7,"is_corresponding":false},{"id":1281,"name":"Mark G. Kris","orcid":"0000-0002-7317-5341","position":8,"is_corresponding":false},{"id":1788552,"name":"Thomas Stout","orcid":null,"position":9,"is_corresponding":false},{"id":1583189,"name":"Vincent Miller","orcid":null,"position":10,"is_corresponding":false},{"id":1556,"name":"Naiyer Rizvi","orcid":null,"position":11,"is_corresponding":false},{"id":1257,"name":"William Pao","orcid":null,"position":12,"is_corresponding":false},{"id":142199,"name":"Juliann Chmielecki","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib","abstract":"<h4>Introduction</h4>EGFR-mutant lung cancers are sensitive to EGFR tyrosine kinase inhibitors (TKIs). Unfortunately, they develop resistance, often due to acquisition of a second-site mutation (T790M). Current EGFR TKIs select for T790M in preclinical models of acquired resistance. We explored whether all EGFR TKIs similarly select for the T790M mutation using data from early clinical trials and established in vitro models of acquired resistance.<h4>Methods</h4>We analyzed the clinical characteristics of eight patients with metastatic EGFR-mutant lung adenocarcinoma who were treated first-line with XL647 and then progressed. XL647 is an ATP-competitive inhibitor of EGFR, HER2, KDR, and EPHB4. Additional molecular preclinical studies were performed to characterize resistance.<h4>Results</h4>Four patients displayed confirmed partial responses (PRs), three patients had unconfirmed PRs, and one patient displayed stable disease. Only one of five patients' tumor samples available for analysis after disease progression harbored the T790M mutation. Eight patients subsequently received erlotinib, with (n = 3) or without (n = 5) chemotherapy. Three of five patients treated with single-agent erlotinib derived additional benefit, staying on drug up to 9 months. EGFR-mutant PC-9 cells with acquired resistance to XL647 did not harbor the T790M mutation, displayed a distinct mRNA profile from PC-9 cells with T790M-mediated resistance, and were moderately sensitive to erlotinib in growth inhibition assays. Crystal structure analyses of XL647/EGFR T790M did not reveal a different binding mode from that of erlotinib.<h4>Conclusions</h4>The findings of this exploratory study suggest that different EGFR TKIs may select for distinct mechanisms of resistance. These results raise the possibility that different EGFR TKIs could be sequentially used to improve outcomes in patients with EGFR-mutant lung cancer. Further work investigating this hypothesis is warranted.","is_dataset_classified":null,"base_score":3.091042453358316,"endowment":3.091042453358316,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22173702","pmcid":"PMC3261336","openalex_id":"https://openalex.org/W2093652074","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30-CA008748","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U54 CA143798","title":null},{"funder_name":"NCI NIH HHS","grant_id":"CA90949","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P50 CA090949","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P01 CA129243","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P01-CA129243","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U54-CA143798","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA008748","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA068485","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01-CA121210","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30-CA68485","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA121210","title":null},{"funder_name":"National Institutes of Health","grant_id":"6R01CA121210-10","title":"Overcoming acquired resistance to EGFR inhibitors in lung cancer"},{"funder_name":"National Institutes of Health","grant_id":"4U54CA143798-03","title":"Evolutionary Dynamics of Brain, Lung, and Hematopoietic Tumors"},{"funder_name":"National Institutes of Health","grant_id":"3P30CA068485-21S4","title":"Cancer Center Support Grant"},{"funder_name":"National Institutes of Health","grant_id":"2P30CA008748-43","title":"MOUSE GENETICS"},{"funder_name":"National Institutes of Health","grant_id":"5P01CA129243-07","title":"Mechanisms and Modulators of Sensitivity and Resistance to EGFR Inhibitors in Lu"},{"funder_name":"National Institutes of Health","grant_id":"3P30CA068485-23S2","title":"Cancer Center Support Grant"}],"total_grants":18,"fwci":2.2569,"citation_percentile":0.87941872,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":2},{"year":2014,"count":4},{"year":2015,"count":2},{"year":2016,"count":3},{"year":2017,"count":1},{"year":2021,"count":1},{"year":2022,"count":1},{"year":2023,"count":3}],"oa_status":"green","license":"Elsevier Non-Commercial","oa_locations":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3261336/pdf/nihms-338155.pdf","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3261336/pdf/nihms-338155.pdf","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S1556086415332500?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1556086415332500?httpAccept=text/plain","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3261336","host_type":"repository"},{"url":"https://doi.org/10.1097/jto.0b013e31823c5aee","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22173702","host_type":"repository"},{"url":"http://www.jto.org/article/S1556086415332500/pdf","host_type":""},{"url":"http://dx.doi.org/10.1097/jto.0b013e31823c5aee","host_type":""},{"url":"http://dx.doi.org/10.1097/JTO.0b013e31823c5aee","host_type":""},{"url":"https://dx.doi.org/10.1097/jto.0b013e31823c5aee","host_type":""}],"fields_of_study":["Lung Cancer Treatments and Mutations","HER2/EGFR in Cancer Research","Lung Cancer Research Studies","03 medical and health sciences","0302 clinical medicine"],"mesh_terms":["Erlotinib Hydrochloride","Adenocarcinoma","Antineoplastic Combined Chemotherapy Protocols","Humans","Lung Neoplasms","Mutation","Neoplasm Staging","Prognosis","Quinazolines","Tumor Cells, Cultured","Biomarkers, Tumor","Immunoblotting","Clinical Trials, Phase II as Topic","In Situ Hybridization, Fluorescence","Drug Resistance, Neoplasm","Oligonucleotide Array Sequence Analysis","Gene Expression Profiling","Protein Kinase Inhibitors","Azabicyclo Compounds","Small Cell Lung Carcinoma","ErbB Receptors"],"keywords":["Erlotinib","T790M","Medicine","Lung cancer","Osimertinib","Erlotinib Hydrochloride","Adenocarcinoma","Cancer research","Tyrosine-kinase inhibitor","Resistance mutation","Mutation","EGFR inhibitors","Afatinib","Epidermal growth factor receptor","Oncology","Cancer","Pharmacology","Internal medicine","Gefitinib","Biology","Gene","Genetics","Pulmonary and Respiratory Medicine","Lung Neoplasms","Immunoblotting","Clinical Trials, Phase II as Topic","Non-small cell lung cancer","Antineoplastic Combined Chemotherapy Protocols","Biomarkers, Tumor","Humans","EGFR tyrosine kinase inhibitors","Protein Kinase Inhibitors","In Situ Hybridization, Fluorescence","Neoplasm Staging","Oligonucleotide Array Sequence Analysis","Gene Expression Profiling","Prognosis","EGFR mutations","Small Cell Lung Carcinoma","ErbB Receptors","Drug Resistance, Neoplasm","XL647","Quinazolines","Acquired resistance","Azabicyclo Compounds"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-18T14:35:25.390226Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}